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Received September 25, 2012; accepted January 15, 2013AbstractBackground: Interleukin-18 (IL-18) plays an important role in mediating cytokine cascade leading to coronary artery lesions (CALs) in Ka-
wasaki disease (KD). However, our research suggested that the literature regarding IL-18 and KD is limited. Consequently, this study aimed to
evaluate the correlation between IL-18 and CALs in patients with KD.
Methods: In this prospective study of 14 children with KD (seven without and seven with CALs in the acute phase), we obtained patient
measurements of a series of serum IL-18 levels in the acute, subacute, and convalescent phases. Serum IL-18 levels were measured with a Bio-
Plex cytokine assay. Control samples were obtained from 18 febrile children with viral infection.
Results: Compared with febrile controls, patients with acute-stage CALs [postintravenous immunoglobulin (post-IVIG) period] had a signifi-
cantly higher IL-18 level (88.4  20.7 vs 56.0  35.0 pg/mL, p ¼ 0.006). However, those without acute-stage CALs (post-IVIG period) lacked
similarly elevated IL-18 level readings (62.0  40.6 vs 56.0  35.0 pg/mL, p ¼ 0.762). The IL-18 level of patients with acute-stage CALs did
not decrease significantly until the convalescent phase (97.4  55.8 vs 38.7  22.6 pg/mL, p ¼ 0.018), but for those without CALs, it decreased
significantly in the subacute phase (60.2  37.4 vs 23.6  13.8 pg/mL, p ¼ 0.018). In the subacute stage, there was a significant difference of IL-
18 level between patients with and without acute-stage CALs ( p ¼ 0.048).
Conclusion: Our data show that IL-18 levels were elevated in the acute phase of KD and might be related to the formation of CALs.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Kawasaki disease (KD), an acute systemic vasculitis that has
a high rate of incidence in Asian population, occurs primarily in
infants and children under the age of 5.1 KD is characterized by
prolonged fever, diffuse mucosal inflammation, edema of hands* Corresponding author. Dr. Luo-Ping Ger, Department of Medical Educa-
tion and Research, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st
Road, Kaohsiung 813, Taiwan, ROC.
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1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.04.005and feet, skin rash, and nonsuppurative lymphadenopathy.1 The
disease is liable to be complicated by development of coronary
artery lesions (CALs), which develop in approximately
15e25% of untreated KD children2 and in approximately 5% of
those after intravenous immunoglobulin (IVIG) therapy.3e5
Although the etiology of KD remains unknown, it may be
attributed to the combined effects of infection, immune
response, and genetic susceptibility.1
Many studies have suggested that immune activation and the
secretion of cytokines may contribute to the pathogenesis of
KD. Activation of the immune system, including neutrophilshinese Medical Association. All rights reserved.
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development of CALs in patients with KD.1,6,7 The immune
response is characterized by increased amounts of several cy-
tokines, such as interleukin-1 (IL-1), tumor necrosis factor
(TNF)-a, interferon-g (IFN-g), IL-4, IL-6, IL-8, IL-10, IL-18,
and a variety of other cytokines.8e13 IL-18, a proinflammatory
member of the IL-1 cytokine superfamily, can induce the pro-
duction of IFN-g in the presence of IL-12 and co-stimulants.14
Furthermore, IL-18 activates T cells to synthesize IL-2 and
TNF-a, enhances the differentiation of T cells into the Th1
phenotype, and suppresses the production of the anti-
inflammatory cytokine IL-10.15e17
IL-18 had been reported to be associated with development
of multiple diseases, such as autoimmune diseases, inflam-
mation, infection, and coronary artery disease (CAD).18e22
However, the literature regarding the association between
IL-18 and KD is limited.13,23 Nomura et al demonstrated that
patients with KD showed normal IL-18 values in the acute
phase and increased values in the subacute phase.13 They
concluded that IL-18 pathways were activated in the subacute
phase of KD, and that subacute IL-18 values might be re-
flected in the severity of KD.13 Chen et al indicated that
105A/C polymorphism and the haplotypes in the IL-18 gene
are associated with the risk of KD in Taiwanese population.23
Although IL-18 is a nonspecific biomarker for inflammation, it
may be a key factor that is associated with cytokine storm in
conditions of acute KD. The clinical implication of IL-18 in
KD may contribute to the scoring system for KD severity and
provide additional anti-inflammatory therapy in IVIG-resistant
patients. In this study, we aimed to evaluate the correlations
between IL-18 and CALs in KD.
2. Methods2.1. PatientsWe recruited 14 children with KD, who were treated with
IVIG (2 g/kg) in the acute stage at the Department of Pediatrics,
Kaohsiung Veterans General Hospital (KVGH), Taiwan, be-
tween October 2008 and March 2011. Medical records were
reviewed for age, gender, presenting symptoms, doses of IVIG
treatment, complications, and laboratory data including base-
line white blood cell (WBC), platelet count, hemoglobin level,
alanine aminotransferase (ALT) (glutamic-pyruvic trans-
aminase) level, aspartate aminotransferase (AST) (glutamic-
oxaloacetic transaminase) level, lipid profile, and C-reactive
protein (CRP) level. The average time from fever onset to IVIG
therapy is 6.29  1.98 days, ranging from 4 to 10 days. Resis-
tance to IVIG is defined as persistent fever for 3 days after initial
IVIG administration. All children with KD underwent two-
dimensional echocardiography during diagnosis and again at
weeks 2, 4, 8, and 12 following the treatment, the 6thmonth, and
annually during follow-up. CALs in the acute stage and chronic
stage are defined as CALs within 2 weeks of illness and beyond
1 year, separately. The internal diameter of the coronary arteries
was measured and CALs were defined as follows: coronary
arteries were classified as abnormal if the internal lumendiameter was 3 mm in children younger than 5 or 4 mm in
children older than 5 years of age, if the internal diameter of a
segment measured 1.5 times that of an adjacent segment, or if
the coronary lumen was clearly irregular.24 Febrile controls
included 18 children who had viral infection and were previ-
ously healthy. This study was carried out after obtaining
approval from the Institutional Review Board of the KVGH.2.2. Sample collectionBlood samples (approximately 3 mL) were collected in the
pre-IVIG acute phase (5.1  1.9 days from fever onset), post-
IVIG acute phase (8.4  2.1 days from fever onset), subacute
phase (44.1  22.2 days from fever onset), and convalescent
stage (199.9  108.1 days from fever onset) after obtaining
informed consent from the parents. Blood samples (approxi-
mately 3 mL) were collected once in the acute stage (4.7  1.6
days from fever) after obtaining informed consent from febrile
control patients with viral infection. The samples were pro-
cessed, separated into aliquots of 1 mL, and then frozen
to 80 C until IL-18 analysis.2.3. Detection of IL-18The IL-18 standards and samples weremeasured in duplicate
with a Bio-Plex Pro Human Cytokine Assay (Bio-Rad Labo-
ratories, Hercules, CA, USA). In brief, the IL-18 standards
(n¼ 16) and samples diluted in serum diluent were added to two
96-well filter plates and incubated with the antibody-coupled
beads for 1 hour with continuous shaking. The beads were
washed three times with wash buffer to remove unbound protein
and incubated with biotinylated detection antibodies for 30
minutes with continuous shaking. Following three washes,
premixed streptavidin phycoerythrin was added to each well
and incubated for 30 minutes. After incubation, the beads were
washed and re-suspended in an assay buffer. The reaction
mixture was quantified using the Bio-Plex protein array reader.
The IL-18 level was automatically calculated by Bio-Plex
Manager software using the appropriate standard curve.
The detection limit of IL-18 was 1.8 pg/mL.2.4. Statistical analysisData are presented as mean  standard deviation. Student t
test, Chi-square test, Wilcoxon signed-rank test, and Man-
neWhitney U test were used to determine differences in age,
gender, and laboratory data between patients and controls. The
correlation between IL-18 and laboratory data was analyzed
by Spearman rank correlation test. A p value <0.05 was taken
to be significant.
3. Results3.1. Patient characteristicsThere were 14 KD patients (2.90  3.44 years, M/F 11/3)
and 18 febrile controls with viral infection (2.51  1.56 years,
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which regressed in the chronic stage. The remaining seven KD
patients had no CALs, and no KD patients had IVIG resis-
tance. There was no significant difference between the two
groups in terms of age and gender (Table 1).3.2. Comparison of IL-18 and CRP levels between
febrile controls and KD patients in various phasesThere was no significant difference between KD patients
before IVIG treatment and febrile controls in terms of IL-18
level (76.2  47.6 vs 56.0  35.0 pg/mL, p ¼ 0.214)
(Table 2). In an acute phase of KD, the IL-18 level was not
significantly lower in the post-IVIG period than that in the pre-
IVIG period (72.0  38.4 vs 76.2  47.6 pg/mL, p ¼ 0.499)
(Fig. 1), but the CRP level was significantly lower in the post-
IVIG period than that in the pre-IVIG period (10.9  7.1 vs
4.1  3.0 mg/dL, p ¼ 0.004) (Fig. 2). In KD patients, both
IL-18 and CRP levels were significantly lower in the
subacute and convalescent phases than that in the acute phases
(pre-IVIG or post-IVIG period) (all p < 0.01) (Table 2).3.3. Comparison of IL-18 and CRP levels between
febrile controls and KD patients with/without CALs in
various phasesTable 3 shows a comparison of IL-18 and CRP levels be-
tween febrile controls and KD patients with/without CALs in
various phases. Compared with febrile controls, patients with
CALs in the acute stage (post-IVIG period) had a significantly
higher IL-18 level (88.4  20.7 vs 56.0  35.0 pg/mL,
p ¼ 0.006), but those without CALs in the acute stage (post-
IVIG period) did not have a similarly higher level (62.0  40.6
vs 56.0  35.0 pg/mL, p ¼ 0.762). In patients with acute-stage
CALs, the IL-18 level in acute stage did not decrease signif-
icantly until the convalescent phase (97.4  55.8 vs
38.7  22.6 pg/mL, p ¼ 0.018), but CRP level significantly
decreased in the acute phase (10.67  8.10 vs
3.80  2.62 mg/dL, p ¼ 0.011). In patients without CALs, the
IL-18 level in acute stage did not decrease significantly until
the subacute phase (60.2  37.4 vs 23.6  13.8 pg/mL,
p ¼ 0.018), but the CRP level significantly decreased in theTable 1
Baseline characteristics of Kawasaki disease patients and febrile children.
Kawasaki disease Febrile controls p
N (%) N (%)
Age 2.9  3.4 2.5  1.6 0.494a
Gender
Male 11 (78.6) 9 (50) 0.098
Female 3 (21.4) 9 (50) d
With acute CALs 7 (50.0) d d
Without CALs 7 (50.0) d d
CALs ¼ coronary artery lesions.
a The p value was estimated by ManneWhitney U test.acute phase (11.1  6.5 vs 4.4  3.5 mg/dL, p ¼ 0.018). In the
subacute stage, there was a significant difference of IL-18
level between patients with and without acute CALs
( p ¼ 0.048) (Fig. 3).3.4. Correlation between IL-18 and laboratory data of
KD patients in pre-IVIG acute phaseTable 4 shows the correlation between IL-18 and laboratory
data values in the pre-IVIG acute phase. The IL-18 level
negatively correlated to hemoglobin level, but the significance
was borderline (r ¼ 0.514, p ¼ 0.060). There is no signifi-
cant correlation between the IL-18 and other laboratory data
values.3.5. Correlation between IL-18 and CRP at various
phases of KDTable 5 showed the correlation between IL-18 and CRP at
various phases of KD. There was no significant correlation be-
tween the levels of IL-18 and CRP in different phases of KD.
4. Discussion
Our study showed elevated values of IL-18 in the acute
phase of KD, which gradually decreased. Compared with the
febrile controls, patients with CALs in the acute stage had a
significantly higher IL-18 level, but those without CALs in the
acute stage had not. In an acute phase of KD, the IL-18 level
after IVIG treatment was not significantly lower than that
before IVIG treatment, but the CRP level after IVIG was
significantly lower than that before IVIG treatment. CRP is not
correlated to IL-18 in various phases of KD. The IL-18 level in
patients without CALs decreased significantly in the subacute
phase, but in those with acute CALs it did not decrease
significantly until the convalescent phase. In the subacute
stage, there was a significant difference of IL-18 level between
patients with and without acute CALs. In this study, longitu-
dinal measurement of IL-18 suggests that IL-18 pathway is
activated in acute-stage KD and there might be an association
between IL-18 and risk of CALs.
The literature regarding the effect of IL-18 in KD is
scant.13,23 In contrast to our findings, Nomura et al demon-
strated that patients with KD showed normal IL-18 values in
the acute phase.13 They speculated that the idea of transient
infiltration of activated IFN-g-producing cells in the study by
Hahn and co-workers25 could not be applied to explain the
normal IL-18 values in acute KD.13 According to them,
normal IL-18 values in the acute phase of KD might be a result
of a kind of negative feedback mechanism of IL-18 path-
ways.13 Three factors may partially explain the discrepancy
between the study results of Nomura and co-workers13 and
ours. First, the measurement of IL-18 is different in terms of
the method used (enzyme-linked immunosorbent assay vs Bio-
Plex) and stored sample temperature (30C vs. 80C) in
two studies. Stored temperature can affect the stability of
cytokines.26 Most cytokines are recommended to be stored
Table 2
Comparison of IL-18 and CRP levels between febrile controls and patients with Kawasaki disease in various phases.
Protein Febrile controls KD patients
Pre-IVIG Post-IVIG Subacute Convalescent
N ¼ 18 N ¼ 14 N ¼ 14 N ¼ 14 N ¼ 14
IL-18 (pg/mL) 56.0  35.0* 78.8  49.5** 75.2  33.9*** 39.9  31.1**,*** 30.7  18.6*,**,***
CRP (mg/dL) 2.4  3.7y 10.9  7.1y,yy 4.1  3.0y,yy,x 0.10  0.10y,yy,x,xx 0.05  0.11y,yy,x,xx
Values are expressed as the mean  standard deviation.
*p ¼ 0.009.
**p ¼ 0.001e0.004.
***p ¼ 0.001.
yp & 0.001
yy p ¼ 0.001e0.004.
xp ¼ 0.001.
xxp ¼ 0.034.
441K.-P. Weng et al. / Journal of the Chinese Medical Association 76 (2013) 438e445at 80C.27 Consequently, storage at 80C may be the su-
perior method to best and most accurately determine IL-18.
Second, the sampling time between the two studies is also
different. Their sampling time in the acute phase is earlier than
ours (4.3  1.7 vs. 5.1  1.9 days). The subacute phase in the
study by Nomura and co-workers occurred much earlier than
that in this series (13.3  3.4 vs 44.1  22.2 days), and similar
to our post-IVIG period in the acute stage (13.3  3.4 vs.Fig. 1. Plasma interleukin-18 (IL-18) levels in febrile controls and Kawasaki
disease (KD) children in various phases. Central box, values from the lower to
upper quartile (25the75th percentile). In the box plots, the middle line rep-
resents the median. An outside value is defined as a value that is smaller than
the lower quartile minus 1.5 times the interquartile range, or larger than the
upper quartile plus 1.5 times the interquartile range (inner fences). These
values are plotted with a round marker. A far out value is defined as a value
that is smaller than the lower quartile minus three times the interquartile range,
or larger than the upper quartile plus three times the interquartile range (outer
fences). These values are plotted with an asterisk marker. In the acute phase of
KD, the IL-18 level was not significantly lower in the postintravenous
immunoglobulin (post-IVIG) period than that in the pre-IVIG period.
(72.0  38.4 vs 76.2  47.6 pg/mL, p ¼ 0.499).8.43  2.1 days). Third, the patients in their study were
Japanese,13 whereas those patients in our study were all
Taiwanese. Cytokines such as IL-1, TNF-a, IFN-g, IL-4, IL-6,
IL-8, IL-10, and a variety of other cytokines have been shown
to increase significantly during acute KD.8e12 They are
believed to play important roles in the onset of KD. The IL-18,
a member of the IL-1 family, might be theoretically elevated in
the acute phase of KD. Elevated IL-18 levels were found in the
acute phase of other diseases and considered as an indicator of
disease activity.19,20 Further studies are needed to demonstrate
IL-18 levels in various phases of KD.
In this series, acute-phase patients with CALs showed a
higher mean IL-18 value than that of febrile controls. The
specificity of IL-18 in terms of etiologic distinction of KD
patients and febrile controls remains cumbersome, and furtherFig. 2. C-reactive protein (CRP) levels in febrile controls and children with
Kawasaki disease (KD) in various phases. In the acute phase of KD, CRP level
was significantly lower in the postintravenous immunoglobulin (post-IVIG)
period than that in the pre-IVIG period (10.9  7.1 vs 4.1  3.0 mg/dL,
p < 0.01). Box plots were constructed as in Fig. 1.
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Fig. 3. Comparison of interleukin-18 (IL-18) levels between patients with and
without acute coronary artery lesions (CALs). In the subacute stage, there was
a significant difference in the IL-18 level between patients with and without
acute CALs ( p ¼ 0.048). Box plots were constructed as in Fig. 1.
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level of patients with CALs did not decrease significantly
until the convalescent stage, but for those without CALs it
significantly decreased in the subacute phase. There was a
significant difference in levels of IL-18 between patients withTable 4
Correlation between IL-18 and laboratory data of patients with Kawasaki
disease in the pre-IVIG acute phase.
Variables Correlation coefficienta p
White blood cell 0.011 0.970
Hemoglobin 0.514 0.060
Platelet 0.244 0.401
GOT 0.007 0.982
GPT 0.081 0.782
Albumin 0.159 0.586
CRP 0.138 0.637
Triglyceride 0.211 0.468
Total cholesterol 0.020 0.946
HDL-C 0.287 0.320
LDL-C 0.037 0.899
CRP ¼ C-reactive protein; GOT ¼ glutamic-oxaloacetic transaminase
(aspartate aminotransferase); GPT ¼ glutamic-pyruvic transaminase (alanine
aminotransferase); HDL-C ¼ high-density lipoprotein cholesterol; IL-
18 ¼ interleukin-18; IVIG ¼ intravenous immunoglobulin; LDL-C ¼ low-
density lipoprotein cholesterol.
a The correlation coefficient and p were estimated by Spearman rank cor-
relation coefficient.
Table 5
Correlation of IL-18 and CRP in various phases of Kawasaki disease.
Correlation coefficienta P
Pre-IVIG acute phase 0.068 0.817
Post-IVIG acute phase 0.000 1.000
Subacute phase 0.081 0.782
Convalescent phase 0.377 0.185
CRP ¼ C-reactive protein; IL-18 ¼ interleukin-18; IVIG ¼ intravenous
immunoglobulin.
a The correlation coefficient and p were estimated by Spearman rank cor-
relation coefficient.
443K.-P. Weng et al. / Journal of the Chinese Medical Association 76 (2013) 438e445and without acute CALs only in the subacute stage. The small
cohort size and large standard deviation might be a cause for
no statistically significant difference in other stages. However,
the mechanism of IL-18 in the formation of CALs is unclear.
Hahn et al demonstrated that IFN-g levels increased in acute
KD and might play an important role in KD-related vascu-
litis.25 We speculate that the effect of IL-18 on the coronary
artery may be mediated by the induction of IFN-g production
and suppression of IL-10. Furthermore, the IL-18 level is not
correlated to the CRP level in various phases of KD. Our
results suggest that activation of IL-18 pathway may be
related to the formation of CALs in the acute stage and in-
dependent of the risk factor of CRP. In contrast to our find-
ings, Nomura et al reported IL-18 values after IVIG in the
subacute phase to be elevated, and to be significantly corre-
lated with the values of WBC and CRP.13 It is difficult to
explain the discrepancy between the study results of Nomura
and co-workers13 and this study. The relation between IL-18
and CAD had been studied previously.21,22 Animal studies
in atherosclerosis support the proatherogenic role of IL-1828
and the beneficial effect of inhibiting IL-18 on plaque pro-
gression and composition.29 Blankenberg et al reported that
the IL-18 level was a strong independent risk factor in pa-
tients with CAD and remained unaffected by various markers
of inflammation such as CRP.21 By contrast, IL-18 suppresses
the production of the anti-inflammatory cytokine IL-10.17
Anguera et al showed lower levels of IL-10 in patients with
unstable angina who subsequently had cardiovascular
events.30 Weng et al reported that the ACC haplotype of IL-10
polymorphism (high production of IL-10) may be a genetic
marker related to reduced risk of acute CALs in KD.31 These
previous studies may support the hypothesis that a pathway
for signaling in CALs in acute KD involves IL-18 to mediate
the inflammation by stimulating or suppressing other cyto-
kines. Further study including measurement of other cyto-
kines is necessary to elucidate the role of IL-18 in acute CALs
in KD.
CRP is a powerful marker of acute KD. The increment of
CRP is related to the rise of plasma IL-6, which is produced
predominantly by macrophages.32 CRP has been incorporated
in some scoring systems for predicting IVIG resistance in KD
treatment. Fukunishi et al reported that patients with a CRP >
10 mg/dL, lactate dehydrogenase >590 IU/L, and/or hemo-
globin level <10 g/dL are considered resistant to IVIG.33
Kobayashi et al designed a seven-variable logistic modelwith high sensitivity and specificity, including day of illness at
initial treatment, age in months, neutrophil count, platelet
count, AST, sodium, and CRP.34 Sano et al showed that pa-
tients with at least two of the three predictors (CRP  7.0 mg,
total bilirubin 0.9 mg, or AST  200 IU/L) are considered to
be resistant to IVIG for acute KD.35 Egami et al demonstrated
that resistance to IVIG treatment can be predicted using age,
illness days, platelet count, ALT, and CRP.36 The predictive
value of these scoring systems is variable, especially in
different ethnic populations.37 Our results showed that CRP is
not correlated to IL-18 in various stages of KD. In the acute
stage, the IL-18 level after IVIG was not significantly lower
than that before IVIG treatment, but the CRP level after IVIG
was significantly lower than that before IVIG treatment. The
IL-18 belongs to the IL-1 superfamily and can induce the
production of IFN-g in the presence of IL-12 and co-stimu-
lants.14 The function of IL-18 is different from that of CRP in
the pathogenesis of KD. This may partially account for the lack
of significant correlation between IL-18 and CRP levels in this
series. The correlation between IL-18 and IVIG resistance is
another interesting issue, but merits further investigation.
This study demonstrated a correlation between anemia and
IL-18 level in acute KD, but the correlation was borderline
statistically significant. Anemia may develop, usually with
normal red blood cell indexes, particularly with an extended
duration of active inflammation.1 Severe anemia is rare and
may be related to macrophage-activation syndrome or IVIG
infusion.38,39 Although anemia is an important laboratory
finding in acute KD, the exact mechanism of anemia remains
unclear. Macrophages have been shown to have a negative
regulation of the growth and development of mature erythroid
progenitors [erythrocyte colony-forming unit (CFU-E)] in
normal and erythroleukemic mice.40 In animal models,
administration of IL-1 induces anemia by suppressing the
activity of CFU-E.40 The activity of IL-18, a member of the
IL-1 family, has also been implicated in hematopoietic pro-
genitor cell growth,41 but its role in erythropoiesis is unclear.
The IL-18 receptors are expressed constitutively in macro-
phages, and/or its lineage,42 and may be involved in the ac-
tivity of macrophage. It is therefore possible that a regulatory
axis related to IL-18 plays a role in the control of erythro-
poiesis and provides a mechanism for the hematopoietic
response to acute inflammation in KD, and the pathogenesis of
the anemia.
Some limitations in this study need to be specified. This is a
single-center investigation with a limited number of patients.
The discrepancy between the results of the study by Nomura
and co-workers13 and this study cannot be well explained
because of inconsistency in the populations studied and the
methods chosen. The difference in IL-18 levels between KD
patients and febrile controls is not elucidated clearly. Because
there was no IVIG-resistant patient in this series, we could not
define the relationship between IL-18 and IVIG resistance.
Measurement of IL-18 was performed on samples that were
stored at 80C. However, the possibility of protein degra-
dation in the stored samples cannot be excluded. A multicenter
study with a large cohort is suggested.
444 K.-P. Weng et al. / Journal of the Chinese Medical Association 76 (2013) 438e445In conclusion, the results of this study show that IL-18
levels were elevated in the acute phase of KD and might be
related to the formation of CALs.
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